NCT04218123View on ClinicalTrials.gov

Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

September 13, 2023

Study Completion Date

September 14, 2023

Conditions
Meniere Disease
Interventions
DRUG

Venlafaxine

Daily oral intake 37.5 mg

DRUG

Placebo oral tablet

Daily oral intake

Trial Locations (1)

29425

Medical Univeristy of South Carolina, Charleston

Sponsors
All Listed Sponsors
collaborator

American Hearing Research Foundation

OTHER

collaborator

Cures Within Reach

OTHER

lead

Medical University of South Carolina

OTHER